MX2017008455A - Tratamiento con antagonista del receptor de oxitocina en la fase lutea para la implatacion y embarazo en mujeres sometidas a tratamiento con tecnologias de reproduccion asistida. - Google Patents

Tratamiento con antagonista del receptor de oxitocina en la fase lutea para la implatacion y embarazo en mujeres sometidas a tratamiento con tecnologias de reproduccion asistida.

Info

Publication number
MX2017008455A
MX2017008455A MX2017008455A MX2017008455A MX2017008455A MX 2017008455 A MX2017008455 A MX 2017008455A MX 2017008455 A MX2017008455 A MX 2017008455A MX 2017008455 A MX2017008455 A MX 2017008455A MX 2017008455 A MX2017008455 A MX 2017008455A
Authority
MX
Mexico
Prior art keywords
treatment
rate
increase
antagonist
oxitocine
Prior art date
Application number
MX2017008455A
Other languages
English (en)
Other versions
MX374877B (es
Inventor
Arce Joan-Carles
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2017008455A publication Critical patent/MX2017008455A/es
Publication of MX374877B publication Critical patent/MX374877B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/42—Gynaecological or obstetrical instruments or methods
    • A61B17/425—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
    • A61B17/435—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for embryo or ova transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al uso de un antagonista del receptor de oxitocina en hembras que se someten a trasferencia embrionaria como parte de una tecnología de reproducción asistida. En particular, se proporcionan métodos para aumentar la tasa de implantación en curso, aumentar la tasa de embarazos en curso, aumentar la tasa de embarazos clínicos y/o aumentar la tasa de nacidos vivos en un sujeto hembra que se somete a transferencia embrionaria. Específicamente, los antagonistas se liberan en la fase lútea cuando el endometrio es receptivo para la implantación del embrión y/o cuando el embrión ha alcanzado la fase de blastocisto.
MX2017008455A 2014-12-22 2015-12-21 Tratamiento con antagonista del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres sometidas a tratamiento con tecnologías de reproducción asistida. MX374877B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199709.8A EP3037101B1 (en) 2014-12-22 2014-12-22 Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
US14/643,307 US9579305B2 (en) 2014-12-22 2015-03-10 Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
PCT/NL2015/050893 WO2016105190A1 (en) 2014-12-22 2015-12-21 Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies

Publications (2)

Publication Number Publication Date
MX2017008455A true MX2017008455A (es) 2018-04-26
MX374877B MX374877B (es) 2025-03-06

Family

ID=52338895

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008455A MX374877B (es) 2014-12-22 2015-12-21 Tratamiento con antagonista del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres sometidas a tratamiento con tecnologías de reproducción asistida.

Country Status (21)

Country Link
US (4) US9579305B2 (es)
EP (2) EP3501533B1 (es)
JP (2) JP6858130B2 (es)
KR (1) KR102715569B1 (es)
CN (2) CN107249618B (es)
AU (1) AU2015367900B2 (es)
BR (1) BR112017013521A2 (es)
CA (1) CA2971846A1 (es)
CL (1) CL2017001640A1 (es)
EA (1) EA201791361A1 (es)
ES (2) ES2716862T3 (es)
IL (1) IL253078B (es)
MX (1) MX374877B (es)
MY (1) MY181349A (es)
PH (1) PH12017550030B1 (es)
PL (1) PL3037101T3 (es)
SG (1) SG11201705175RA (es)
TW (1) TWI702043B (es)
UA (1) UA125492C2 (es)
WO (1) WO2016105190A1 (es)
ZA (1) ZA201704958B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
AU2015283133B2 (en) 2014-07-02 2019-05-16 ObsEva SA Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime useful in methods of treating conditions related to the OT-R activity
ES2716862T3 (es) 2014-12-22 2019-06-17 Ferring Bv Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida
JP6933322B2 (ja) 2016-01-04 2021-09-08 メルク セローノ エス．エー． ヒドロキシプロピルチアゾリジンカルボキサミド誘導体のｌ−バリネート及びその塩形態、結晶多形
CN115590849A (zh) 2016-07-21 2023-01-13 奥布赛瓦股份公司（Ch） 促进胚胎植入和预防流产的催产素拮抗剂给药方案
CA3149898A1 (en) 2019-09-03 2021-03-11 Ernest Loumaye Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
WO2021160597A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy
CN116157153B (zh) * 2020-10-28 2026-04-14 国立大学法人东海国立大学机构 恶性间皮瘤的治疗剂以及恶性间皮瘤患者的选择方法
CN114292907A (zh) * 2020-12-15 2022-04-08 苏州亿康医学检验有限公司 用于反复植入失败的生物标志物和诊断与治疗方法
CN117531006B (zh) * 2023-10-10 2025-02-11 山东奥克斯畜牧种业有限公司 一种提高牛胚胎移植受胎率的组合制剂及其制备方法与应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604341D0 (sv) 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
AUPP421298A0 (en) 1998-06-19 1998-07-09 Fertilitescentrum Ab Method and medium for in vitro culture of human embryos
PL361689A1 (en) * 2001-01-09 2004-10-04 Schering Aktiengesellschaft The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
US7402558B2 (en) * 2001-09-12 2008-07-22 Laboratoires Seronosa Method for aiding implantation or decreasing miscarriage rate
EP1480998B1 (en) 2002-02-27 2006-11-22 Ferring BV Intermediates and methods for making heptapeptide oxytocin analogues
UA78058C2 (en) * 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
FR2849380A1 (fr) * 2002-12-27 2004-07-02 Ernest Loumaye NOUVELLE UTILISATION D'UN AGONISTE DU GnRH
US7111275B2 (en) 2003-08-28 2006-09-19 International Business Machines Corporation Electronic circuit design analysis system
JP2007505919A (ja) 2003-09-18 2007-03-15 アクシス・ファーマシューティカルズ・インコーポレイテッド システイン・プロテアーゼ阻害剤としてのハロアルキル含有化合物
BRPI0414663A (pt) 2003-09-22 2006-11-21 Pfizer derivados triazol substituìdos como antagonistas de oxitocina
EP1555029A1 (en) 2004-01-19 2005-07-20 Ferring B.V. Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension
US20080318847A1 (en) * 2005-05-10 2008-12-25 Ferring International Center Sa Use of Antagonist of Oxytocin and/or Vasopressin in Assisted Reproduction
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
WO2010130008A1 (en) 2009-05-14 2010-11-18 Adelaide Research & Innovation Pty Ltd Methods for the collection and maturation of oocytes
JP6186353B2 (ja) 2011-07-01 2017-08-23 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ヒト卵丘細胞の発生ステージを決定するための方法
US10271876B2 (en) 2011-11-23 2019-04-30 Mezadata Medical Ip Holding Llc Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells
WO2013181549A2 (en) 2012-05-31 2013-12-05 Auxogyn, Inc. In vitro embryo blastocyst prediction methods
EP2922475A1 (en) 2012-11-26 2015-09-30 Ferring BV Method and system for diagnosing uterine contraction levels using image analysis
ES2716862T3 (es) 2014-12-22 2019-06-17 Ferring Bv Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida

Also Published As

Publication number Publication date
PH12017550030B1 (en) 2024-07-03
ES3041573T3 (en) 2025-11-13
MY181349A (en) 2020-12-21
UA125492C2 (uk) 2022-04-13
AU2015367900B2 (en) 2021-05-13
ES2716862T3 (es) 2019-06-17
CA2971846A1 (en) 2016-06-30
EP3501533B1 (en) 2025-07-09
US20170348325A1 (en) 2017-12-07
US10688106B2 (en) 2020-06-23
NZ733869A (en) 2020-10-30
US10183029B2 (en) 2019-01-22
TW201636016A (zh) 2016-10-16
IL253078A0 (en) 2017-08-31
US20170189415A1 (en) 2017-07-06
TWI702043B (zh) 2020-08-21
MX374877B (es) 2025-03-06
EA201791361A1 (ru) 2017-11-30
IL253078B (en) 2020-04-30
US20200352962A1 (en) 2020-11-12
KR20170135821A (ko) 2017-12-08
US20160175283A1 (en) 2016-06-23
CN113940990A (zh) 2022-01-18
WO2016105190A1 (en) 2016-06-30
BR112017013521A2 (pt) 2018-03-06
US11752157B2 (en) 2023-09-12
JP2021054863A (ja) 2021-04-08
SG11201705175RA (en) 2017-07-28
CL2017001640A1 (es) 2018-01-26
JP2018505212A (ja) 2018-02-22
EP3037101B1 (en) 2019-03-06
EP3037101A1 (en) 2016-06-29
ZA201704958B (en) 2019-10-30
PL3037101T3 (pl) 2019-06-28
CN107249618B (zh) 2021-11-16
CN107249618A (zh) 2017-10-13
EP3501533A1 (en) 2019-06-26
JP6858130B2 (ja) 2021-04-14
AU2015367900A1 (en) 2017-08-03
PH12017550030A1 (en) 2018-01-15
KR102715569B1 (ko) 2024-10-11
US9579305B2 (en) 2017-02-28
JP7184935B2 (ja) 2022-12-06

Similar Documents

Publication Publication Date Title
MX2017008455A (es) Tratamiento con antagonista del receptor de oxitocina en la fase lutea para la implatacion y embarazo en mujeres sometidas a tratamiento con tecnologias de reproduccion asistida.
Galliano et al. MicroRNA and implantation
MX2020001450A (es) Composiciones para reducir la inmunosupresion por celulas de tumor.
BR112018068126A2 (pt) sistemas e métodos para a produção e liberação de pasta fluida gelada medicinal
CL2017000053A1 (es) Anticuerpos de unión a protofibrillas aß
MX2021008755A (es) Un anticuerpo anti-tau para usarse al tratar una tauopatia.
MX2018008106A (es) Terapias con celulas inmunoefectoras de una eficacia mejorada.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
MX380555B (es) Combinación de anticuerpos anti-gen 3 de la activación de linfocito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
UY36455A (es) Antagonistas del receptor ep3 de prostaglandinas
CL2015003402A1 (es) Células madres adultas adiposas, humanas, pluripotentes: aislamiento, caracterización e implicaciones clinicas
UY35776A (es) ?antagonistas de receptor ep3 de prostaglandina?.
CO7111317A2 (es) Método para el tratamiento de enfermedades ginecológicas
MX390977B (es) Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontan que utilizan composiciones de udenafilo
MX2017001632A (es) Mioinositol y probioticos, y uso de estos.
UY36385A (es) Piperidinilpirazolopirimidinonas y utilización de las mismas
IL250212B (en) Tungsten salts (vi) for use in the treatment of infertility, to favor normal fertility and reproduction in the female of non-diabetic mammals, as well as to improve the efficiency of assisted reproduction techniques
AR095834A1 (es) Forma de dosificación de un antagonista del receptor de progesterona, composición farmacéutica
BR112016029661A2 (pt) retosiban para tratamento de parto prematuro
UY35584A (es) Composición farmacéutica, su uso y régimen de administración para contracepción programada
CL2015002365A1 (es) Métodos para uso de semen sexado para mejorar la gestión genética en cerdos
AR097287A1 (es) Modulador de los receptores de somatostatina para tratar la infertilidad
CO2017003561A2 (es) Uso del ácido neridrónico o de su sal para el tratamiento de la osteoartrosis
CR20150530A (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina

Legal Events

Date Code Title Description
FG Grant or registration